Research
Hormonal
GLP-1 agonists and bariatric surgery can achieve high rates of remission, but these are not true remission as they require ongoing treatment, and long-term sustainability is low without continuous intervention.
GLP-1 agonists and surgery are effective for achieving remission, but they are not cures. You will likely need to continue treatment or accept the risks of surgery. Discuss with your doctor whether the benefits of these interventions outweigh the need for ongoing management.
GoodQualifiesHIGH confidence
However, this may not strictly be defined as remission, as these patients are in receipt of therapy... The long-term follow-up in the SOS study reported remission rates of 72% at two years, reducing to 30% at 15 years.
Why this rating
Based on specific trial data (SURMOUNT-2, STEP-2, SOS) cited in the paper.
Source
Is lasting remission feasible in the real-world setting? No!
Kamlesh Khunti · British Journal of Diabetes · 2024
DOI 10.15277/bjd.2024.453
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →